Devonian Health Group Inc. (TSXV:GSD)
Canada · Delayed Price · Currency is CAD 8.14
-1.11 (-12.00%)
At close: Jun 30, 2026
Devonian Health Group Revenue
Devonian Health Group had revenue of 176.64K CAD in the quarter ending April 30, 2026, a decrease of -97.60%. In the fiscal year ending July 31, 2025, Devonian Health Group had annual revenue of 23.59M with 22.19% growth.
Revenue
23.59M
Revenue Growth
+22.19%
P/S Ratio
7.56
Revenue / Employee
299.53K
Employees
11
Market Cap
22.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jul 31, 2025 | 23.59M | 4.28M | 22.19% |
| Jul 31, 2024 | 19.31M | 16.96M | 723.15% |
| Jul 31, 2023 | 2.35M | 40.20K | 1.74% |
| Jul 31, 2022 | 2.31M | 830.50K | 56.32% |
| Jul 31, 2021 | 1.47M | -668.47K | -31.19% |
| Jul 31, 2020 | 2.14M | -1.86M | -46.49% |
| Jul 31, 2019 | 4.00M | 837.06K | 26.42% |
| Jul 31, 2018 | 3.17M | - | - |
| Jul 31, 2017 | - | - | - |
| Jul 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDevonian Health Group News
- 1 day ago - Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026 - PRNewsWire
- 3 months ago - Devonian Reports Results of its Annual General and Special Meeting of Shareholders - PRNewsWire
- 3 months ago - Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026 - PRNewsWire
- 4 months ago - Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects - PRNewsWire
- 4 months ago - Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls - PRNewsWire
- 4 months ago - Devonian reports additional molecular data from MASH liver study - PRNewsWire
- 5 months ago - DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY - PRNewsWire
- 5 months ago - DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT - PRNewsWire